Search
Tirzepatide Treatment Options
A collection of 110 research studies where Tirzepatide is the interventional treatment. These studies are located in the United States . Tirzepatide is used for conditions such as Obesity, Overweight and Type 2 Diabetes.
25 - 36 of 110
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Type 2 Diabetes
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
New High Blood Pressure (Hypertension) Clinical Trials
Recruiting
This campaign features 7 hypertension studies for adults with high blood pressure that remains uncontrolled despite medication. Studies are available for a range of cardiovascular profiles, including people taking multiple blood pressure medications or living with heart or vascular disease.
Inclusion Criteria:
- Diagnosed with high blood pressure (hypertension)
- Age 18+ (one study requires participants to be 55+)
- Blood pressure remains elevated despite taking medication (typically systolic 135 mmHg or higher), or your doctor has expressed concerns about your blood pressure
- Currently taking 2 or more blood pressure medications
- Have cardiovascular disease (such as a previous heart attack, coronary artery disease, stroke, or peripheral artery disease) or certain cardiovascular risk factors, including diabetes, chronic kidney disease (CKD), atrial fibrillation (AF), or smoking (study dependent)
- Stable body weight for the past 3 months
Find out if you qualify today.
Inclusion Criteria:
- Diagnosed with high blood pressure (hypertension)
- Age 18+ (one study requires participants to be 55+)
- Blood pressure remains elevated despite taking medication (typically systolic 135 mmHg or higher), or your doctor has expressed concerns about your blood pressure
- Currently taking 2 or more blood pressure medications
- Have cardiovascular disease (such as a previous heart attack, coronary artery disease, stroke, or peripheral artery disease) or certain cardiovascular risk factors, including diabetes, chronic kidney disease (CKD), atrial fibrillation (AF), or smoking (study dependent)
- Stable body weight for the past 3 months
Find out if you qualify today.
Conditions:
Hypertension Multi
Hypertension
Pulmonary Hypertension
Ocular Hypertension
Pulmonary Arterial Hypertension
Featured Trial
New Obesity Clinical Studies Now Recruiting
Recruiting
We are seeking participants for multiple clinical trials focused on obesity and metabolic health, evaluating investigational treatments for weight management and diabetes. Studies are looking for adults with obesity, with or without type 2 diabetes, who are not currently taking GLP-1 medications or other weight-loss treatments.
See if you qualify today.
See if you qualify today.
Conditions:
Obesity Multi
Obesity
Overweight and Obesity
Morbid Obesity
Childhood Obesity
Featured Trial
Multiple Type 2 Diabetes Studies Now Recruiting
Recruiting
We are seeking participants for 14 clinical studies investigating new treatments for type 2 diabetes (T2DM) and related conditions including obesity and fatty liver disease (MASH/NAFLD). Studies are looking for adults with a confirmed T2DM diagnosis who are not well-controlled or are seeking improved management, spanning a range of disease stages from early/diet-managed to long-standing and multiply medicated.
See if you qualify today.
See if you qualify today.
Conditions:
Type 2 Diabetes Multi
Type 2 Diabetes
Diabete Type 2
Diabetic Nephropathy Type 2
Type 2 Diabetes Mellitus
Featured Trial
Reduce Heart Failure Risk – See if You Qualify for a Study
Recruiting
We are currently looking for individuals aged 18 and older to take part in a heart disease research study. You may be eligible if you have been diagnosed with all of the following:
• Cardiovascular Disease
• Type 2 Diabetes
• High Blood Pressure
This study is exploring an investigational medication that may help reduce the risk of heart-related complications.
If you’re interested in learning more, you can see if you pre-qualify today.
• Cardiovascular Disease
• Type 2 Diabetes
• High Blood Pressure
This study is exploring an investigational medication that may help reduce the risk of heart-related complications.
If you’re interested in learning more, you can see if you pre-qualify today.
Conditions:
Heart Diseases
Congenital Heart Disease
Coronary Heart Disease
Ischemic Heart Disease
Heart Disease
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight.
The maximum duration of this study is up to 61 weeks.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/22/2025
Locations: Digestive Health Specialists, Dothan, Alabama +188 locations
Conditions: Crohn's Disease, Obesity or Overweight
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Recruiting
The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and placebo, leads to decrease or disappearance of UC symptoms, and loss of at least one-tenth of the overall body weight.
Participation in this study will last up to 61 weeks, including 52 weeks of treatment.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/22/2025
Locations: Digestive Health Specialists, Dothan, Alabama +196 locations
Conditions: Ulcerative Colitis, Obesity or Overweight
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
Active Not Recruiting
We are doing this study to learn more about how tirzepatide may help fight chronic kidney disease in people with obesity with or without type 2 diabetes (T2D).
The study will last about 56 weeks and include up to 12 visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Valley Clinical Trials, Inc., Northridge, California +26 locations
Conditions: Overweight, Obesity, Chronic Kidney Disease, Type 2 Diabetes, T2D
Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024
Not Yet Recruiting
This study aims to see if the clinical use of Tirzepatide in patients with lipodystrophy (a rare disorder associated with abnormal loss of the body's fat tissue) may lead to improved diabetes mellitus control and lowering of participant's triglycerides through the reduction of caloric intake.
Study Hypothesis:
- The clinical use of Tirzepatide in patients with lipodystrophy may lead to favorable outcomes through the reduction of caloric intake.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Lipodystrophy, Partial
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
Recruiting
The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Sansum Diabetes Research Institute, Goleta, California +147 locations
Conditions: Type 1 Diabetes, Obesity, Overweight
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
Recruiting
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe PsA and obesity or overweight with at least 1 weight-related comorbidity.
The study will last up to 12 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Avondale, Avondale, Arizona +56 locations
Conditions: Psoriatic Arthritis, Overweight or Obesity
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Recruiting
The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newly enrolled participants across the master and the ISAs. The ISAs may start independently of other ISAs as interventions become available for clinical testing. The results for the CWMM screening record... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/17/2025
Locations: The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler, Arizona +53 locations
Conditions: Obesity, Overweight
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight
Recruiting
The main purpose of this study is to find out how well and how safely tirzepatide works long-term in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 20 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Kaiser Permanente Bonita Medical Offices, Bonita, California +80 locations
Conditions: Type 1 Diabetes, Obesity, Overweight
A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants
Active Not Recruiting
The main purpose of this study is to evaluate the body concentration of different forms of bimagrumab, administered alone or with tirzepatide. Participation in the study will last about 4.5 months, including screening and follow-up.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
07/17/2025
Locations: Fortrea Clinical Research Unit, Dallas, Texas
Conditions: Healthy
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
Recruiting
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity.
The study will last up to 12 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Medical Dermatology Specialists, Phoenix, Arizona +39 locations
Conditions: Psoriasis, Overweight or Obesity
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)
Completed
The main purpose of this study is to investigate the efficacy and safety of switching from weekly dulaglutide to weekly tirzepatide compared to increasing the dulaglutide dose in adults with type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: ALL Medical Research, LLC, Cooper City, Florida +37 locations
Conditions: Type 2 Diabetes
Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese
Completed
A phase 2 study to evaluate the effects of apitegromab as an adjunctive therapy to GLP-1 receptor agonist therapy in subjects with overweight or obesity
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/14/2025
Locations: ProSciento CRU, Chula Vista, California +6 locations
Conditions: Overweight and Obesity
25 - 36 of 110